BridgeBio Pharma Debt to Equity Ratio 2018-2026 | BBIO
Current and historical debt to equity ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. BridgeBio Pharma debt/equity for the three months ending March 31, 2026 was 0.00.
| BridgeBio Pharma Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $3.64B | $-2.27B | -1.61 |
| 2025-12-31 | $3.01B | $-2.08B | -1.45 |
| 2025-09-30 | $2.92B | $-1.92B | -1.52 |
| 2025-06-30 | $2.86B | $-1.78B | -1.61 |
| 2025-03-31 | $2.52B | $-1.64B | -1.54 |
| 2024-12-31 | $2.38B | $-1.46B | -1.63 |
| 2024-09-30 | $1.88B | $-1.22B | -1.55 |
| 2024-06-30 | $1.88B | $-1.08B | -1.73 |
| 2024-03-31 | $1.89B | $-1.04B | -1.82 |
| 2023-12-31 | $1.89B | $-1.34B | -1.41 |
| 2023-09-30 | $1.85B | $-1.20B | -1.55 |
| 2023-06-30 | $1.85B | $-1.35B | -1.37 |
| 2023-03-31 | $1.84B | $-1.21B | -1.52 |
| 2022-12-31 | $1.87B | $-1.24B | -1.50 |
| 2022-09-30 | $1.86B | $-1.13B | -1.65 |
| 2022-06-30 | $1.88B | $-1.01B | -1.85 |
| 2022-03-31 | $1.85B | $-1.04B | -1.78 |
| 2021-12-31 | $1.88B | $-0.87B | -2.17 |
| 2021-09-30 | $1.52B | $-0.74B | -2.06 |
| 2021-06-30 | $1.54B | $-0.46B | -3.36 |
| 2021-03-31 | $1.48B | $-0.39B | -3.81 |
| 2020-12-31 | $0.60B | $0.11B | 5.62 |
| 2020-09-30 | $0.57B | $0.22B | 2.65 |
| 2020-06-30 | $0.58B | $0.33B | 1.78 |
| 2020-03-31 | $0.54B | $0.45B | 1.20 |
| 2019-12-31 | $0.16B | $0.47B | 0.33 |
| 2019-09-30 | $0.12B | $0.52B | 0.23 |
| 2019-06-30 | $0.00B | $0.00B | 0.00 |
| 2019-03-31 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.00B | 0.00 | |
| 2018-09-30 | $0.00B | $0.00B | 0.00 |
| 2017-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |